Page values for "Ticagrelor"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Ticagrelor
brand	`String`	Brilinta
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Antiplatelet_agents\|Antiplatelet agent]] • [[:Category:P2Y12_inhibitors\|P2Y12 receptor inhibitor (reversible)]] • [[:Category:Cyclopentyltriazolopyrimidines\|Cyclopentyltriazolopyrimidine]]
mechanism	`String`
uses	`String`	'"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"'
starting_dose	`String`	ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID
preparations	`String`	60, 90 mg tablets
fda_max	`String`	90 mg BID (acute year); 60 mg BID (chronic post-MI)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Antiplatelet effect within 30 minutes of loading dose (faster than clopidogrel)
duration	`String`	12 hours
halflife	`String`	~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)'"`UNIQ--ref-00000C92-QINU`"'
bioavailability	`String`	~36% (oral)'"`UNIQ--ref-00000C93-QINU`"'
pregnancy	`String`	Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US. Carries a '''Boxed Warning''' for bleeding risk and against aspirin maintenance doses above 100 mg/d (reduces ticagrelor efficacy, per PLATO subgroup analysis)'"`UNIQ--ref-00000C94-QINU`"'